Citadel Advisors’s Celularity CELU Stock Holding History

Citadel Advisors’s Portfolio CELU Stock Details CELU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$59.2K	Buy	+99,054	New	+$95.1K	﹤0.01%	13040
2026 Q1	–	Sell	-77,657	Closed	-$86.2K	–	13088
2025 Q4	$86.2K	Buy	77,657 +32,901	+74%	+$59K	﹤0.01%	11747
2025 Q3	$92.6K	Sell	44,756 -15,012	-25%	-$42K	﹤0.01%	11892
2025 Q2	$117K	Buy	59,768 +12,822	+27%	+$23.3K	﹤0.01%	11190
2025 Q1	$81.2K	Buy	+46,946	New	+$88.9K	﹤0.01%	11744
2024 Q1	–	Sell	-4,981	Closed	-$20.5K	–	14627
2023 Q4	$12.3K	Buy	+4,981	New	+$10.8K	﹤0.01%	12998
2023 Q3	–	Sell	-1,678	Closed	-$6.03K	–	14343
2023 Q2	$8.94K	Buy	+1,678	New	+$10.7K	﹤0.01%	13286
2023 Q1	–	Sell	-3,721	Closed	-$29.9K	–	14775
2022 Q4	$48K	Buy	+3,721	New	+$68.6K	﹤0.01%	12193
2022 Q2	–	Sell	-7,139	Closed	-$580K	–	12963
2022 Q1	$622K	Buy	7,139 +2,598	+57%	+$156K	﹤0.01%	8862
2021 Q4	$232K	Buy	4,541 +1,194	+36%	+$76.3K	﹤0.01%	11536
2021 Q3	$237K	Sell	3,347 -4,703	-58%	-$380K	﹤0.01%	11590
2021 Q2	$819K	Sell	8,050 -23,333	-74%	-$2.36M	﹤0.01%	8883
2021 Q1	$3.16M	Buy	+31,383	New	+$3.22M	﹤0.01%	5314

Other funds holding CELU

CVSC

C.V. Starr & Co New York $187M AUM 26.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BFO

Biltmore Family Office Charlotte, North Carolina $761M AUM 31.91% 1-Year Est. Return

HWM

HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return

Citadel Advisors's CELU Position: Q2 2026 in Review

Citadel Advisors opened a new position in Celularity (CELU) in Q2 2026: 99,054 shares worth $59.2K. The stake represents ﹤0.01% of the portfolio and ranks #13040 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CELU as recently as Q4 2025.

Citadel Advisors first reported a position in CELU in Q1 2021 and has held it in 13 quarters since. The position peaked at $3.16M in Q1 2021. 39 funds tracked by Wall St. Rank hold CELU as of Q2 2026.

Citadel Advisors held 99,054 shares of Celularity worth $59.2K as of Q2 2026.
Celularity was a new Citadel Advisors position in Q2 2026.
Celularity made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13040 holding.
Citadel Advisors first reported a position in Celularity in Q1 2021 and has held it in 13 quarters since.
Citadel Advisors's Celularity position peaked at $3.16M in Q1 2021.
39 funds tracked by Wall St. Rank held Celularity as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.